Octave is Delivering Precision Care to Manage Neurodegenerative Diseases. Learn More

Feb 24th, 2022

Hear directly from Ferhan Qureshi, Octave’s Vice President of Biomarker Production Development, at ACTRIMS Forum 2022 as he discusses our novel multivariate proteomic multiple sclerosis disease activity test (MSDA), which measures the concentration of 18 proteins to determine four disease pathways: immunomodulation, neuroinflammation, myelin biology and neuroaxonal integrity, and an overall disease activity score. Learn more about the MSDA test and our comprehensive 3-part solution from the Video Journal of Neurology: https://bit.ly/34pwb7g

Get in Touch

Please reach out and we’ll be in touch soon.